[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2024, "totalPay": 255941, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "President", "fiscalYear": 2024, "totalPay": 487545, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Mailling", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 210123, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shengnan  Guo", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 10, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.98, "open": 10.9, "dayLow": 10.9, "dayHigh": 11.13, "regularMarketPreviousClose": 10.98, "regularMarketOpen": 10.9, "regularMarketDayLow": 10.9, "regularMarketDayHigh": 11.13, "payoutRatio": 0.0, "beta": 0.838, "trailingPE": 16.61194, "forwardPE": 22.26, "volume": 1793, "regularMarketVolume": 1793, "averageVolume": 12446, "averageVolume10days": 10700, "averageDailyVolume10Day": 10700, "bid": 11.04, "ask": 11.14, "bidSize": 2210, "askSize": 700, "marketCap": 282518752, "fiftyTwoWeekLow": 6.63, "fiftyTwoWeekHigh": 12.5, "allTimeHigh": 18.0, "allTimeLow": 0.3, "priceToSalesTrailing12Months": 5.6441665, "fiftyDayAverage": 10.2914, "twoHundredDayAverage": 9.90435, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 287333120, "profitMargins": 0.34686002, "floatShares": 5399167, "sharesOutstanding": 25369643, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42425, "heldPercentInstitutions": 0.01288, "shortRatio": 0.97, "impliedSharesOutstanding": 25383535, "bookValue": 4.491, "priceToBook": 2.4782898, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 18.438, "netIncomeToCommon": 17362000, "trailingEps": 0.67, "forwardEps": 0.5, "enterpriseToRevenue": 5.74, "enterpriseToEbitda": 14.709, "52WeekChange": 0.10351753, "SandP52WeekChange": 0.17354333, "quoteType": "EQUITY", "currentPrice": 11.13, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "totalCash": 8424000, "totalCashPerShare": 0.332, "ebitda": 19534000, "totalDebt": 13393000, "quickRatio": 0.908, "currentRatio": 1.305, "totalRevenue": 50055000, "debtToEquity": 11.755, "revenuePerShare": 1.96, "returnOnAssets": 0.05298, "returnOnEquity": 0.16318001, "grossProfits": 37201000, "freeCashflow": 22795124, "operatingCashflow": 29883000, "earningsGrowth": 20.0, "revenueGrowth": 0.238, "grossMargins": 0.7432, "ebitdaMargins": 0.39025003, "operatingMargins": 0.38759, "financialCurrency": "USD", "symbol": "CPHRF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "regularMarketChangePercent": 1.3661255, "regularMarketPrice": 11.13, "longName": "Cipher Pharmaceuticals Inc.", "exchange": "OQX", "messageBoardId": "finmb_8201659", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1766782800, "marketState": "CLOSED", "shortName": "Cipher Pharmaceuticals, Inc.", "fiftyDayAverageChange": 0.83860016, "fiftyDayAverageChangePercent": 0.081485525, "twoHundredDayAverageChange": 1.2256498, "twoHundredDayAverageChangePercent": 0.12374864, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1138890600000, "regularMarketChange": 0.15000057, "regularMarketDayRange": "10.9 - 11.13", "fullExchangeName": "OTC Markets OTCQX", "averageDailyVolume3Month": 12446, "fiftyTwoWeekLowChange": 4.5, "fiftyTwoWeekLowChangePercent": 0.678733, "fiftyTwoWeekRange": "6.63 - 12.5", "fiftyTwoWeekHighChange": -1.3699999, "fiftyTwoWeekHighChangePercent": -0.10959999, "fiftyTwoWeekChangePercent": 10.351753, "earningsTimestamp": 1762462800, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "earningsCallTimestampStart": 1762522200, "earningsCallTimestampEnd": 1762522200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.67, "epsForward": 0.5, "displayName": "Cipher Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]